search
Back to results

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

Primary Purpose

Philadelphia-Negative ALL, High-Risk Cancer

Status
Recruiting
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Blinatumomab
Sponsored by
Israeli Medical Association
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Philadelphia-Negative ALL focused on measuring Philadelphia-Negative ALL, Pediatric therapy, Blinatumomab, Allogeneic transplantation

Eligibility Criteria

18 Years - 30 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years and <30 years of age at the time of signing the informed consent document.
  2. Have a documented diagnosis of Ph-neg ALL, LBL or MPAL according to the WHO 2016 classification (appendix I).
  3. Females of childbearing potential (FCBP) may participate, providing they meet the following conditions:

    Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following EOT; and have a negative serum or urine pregnancy test (investigator's discretion; sensitivity at least 25 mIU/mL) at screening; and have a negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting study therapy in the treatment phase (note that the screening serum pregnancy test can be used as the test prior to starting study therapy in treatment phase if it is performed within the 72-hour timeframe).

  4. Male subjects with a female partner of childbearing potential must agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last dose of study drug.
  5. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
  6. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Age <18 or over 30 years at the time of signing the informed consent document.
  2. Ph-positive disease.
  3. Known Human Immunodeficiency Virus (HIV).
  4. Known or suspected hypersensitivity to any of the study drugs.
  5. Pregnant or lactating females.
  6. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  7. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  8. Participation to an investigational drug trial in the last month before randomization.

Sites / Locations

  • Rambam Medical CenterRecruiting
  • Shaarei Tzedek Medical CenterRecruiting
  • Rabin Medical CenterRecruiting
  • Tel Aviv Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Blinatumomab pre-transplant to high risk Ph-negative ALL pts.

Arm Description

Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.

Outcomes

Primary Outcome Measures

Event-free survival (EFS)
Measured from the date of entry on study until treatment failure, relapse from CR, or death from any cause, whichever occurs first

Secondary Outcome Measures

Overall survival (OS)
Measured from the date of entry on study until until death from any cause
Early death during induction
Death during the first 60 days from entering study from any cause
MRD status
MRD status pre- and post-antibody-based therapy

Full Information

First Posted
March 31, 2020
Last Updated
May 6, 2021
Sponsor
Israeli Medical Association
search

1. Study Identification

Unique Protocol Identification Number
NCT04334993
Brief Title
Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
Official Title
A Phase 2, Multicenter, Single Arm Trial to Assess the Safety and Efficacy of a Pediatric Approach to for Young Adults With Acute Lymphoblastic Leukemia With Blinatumomab Therapy for High-risk Patients Prior to Allogeneic Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
May 1, 2023 (Anticipated)
Study Completion Date
May 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Israeli Medical Association

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.
Detailed Description
This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be assessed. Young-adult patients eligible with Ph-neg ALL, LBL and mixed phenotype acute leukemia (MPAL) will undergo risk stratification and started on the pediatric Italian Association of Pediatric Hematology Oncology-Berlin-Frankfurt-Münster (AIEOP-BFM) 2009 protocol. Patients defined as having non-high-risk disease features (non-HR) as defined by MRD and/or cytogenetic criteria will complete the non-HR chemotherapy arm per protocol. Patients designated as having HR disease features after 2 induction blocks will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation. All patients will be centrally assessed for MRD and for Ph-like status.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Philadelphia-Negative ALL, High-Risk Cancer
Keywords
Philadelphia-Negative ALL, Pediatric therapy, Blinatumomab, Allogeneic transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
This is a national, multicenter, phase II clinical trial
Masking
None (Open Label)
Masking Description
NR
Allocation
N/A
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Blinatumomab pre-transplant to high risk Ph-negative ALL pts.
Arm Type
Experimental
Arm Description
Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
Intervention Type
Drug
Intervention Name(s)
Blinatumomab
Other Intervention Name(s)
AIEOP-BFM 2009 protocol - multiagent chemothertapy protocol backbone
Intervention Description
Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
Primary Outcome Measure Information:
Title
Event-free survival (EFS)
Description
Measured from the date of entry on study until treatment failure, relapse from CR, or death from any cause, whichever occurs first
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Overall survival (OS)
Description
Measured from the date of entry on study until until death from any cause
Time Frame
2 years
Title
Early death during induction
Description
Death during the first 60 days from entering study from any cause
Time Frame
60 days
Title
MRD status
Description
MRD status pre- and post-antibody-based therapy
Time Frame
MRD will be assess by PCR after induction I (day 33), after induction II (week 12), after blinatumomab therapy (prior to HSCT) and at days 30 and 100 post alloHSCT.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years and <30 years of age at the time of signing the informed consent document. Have a documented diagnosis of Ph-neg ALL, LBL or MPAL according to the WHO 2016 classification (appendix I). Females of childbearing potential (FCBP) may participate, providing they meet the following conditions: Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following EOT; and have a negative serum or urine pregnancy test (investigator's discretion; sensitivity at least 25 mIU/mL) at screening; and have a negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting study therapy in the treatment phase (note that the screening serum pregnancy test can be used as the test prior to starting study therapy in treatment phase if it is performed within the 72-hour timeframe). Male subjects with a female partner of childbearing potential must agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last dose of study drug. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: Age <18 or over 30 years at the time of signing the informed consent document. Ph-positive disease. Known Human Immunodeficiency Virus (HIV). Known or suspected hypersensitivity to any of the study drugs. Pregnant or lactating females. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. Participation to an investigational drug trial in the last month before randomization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ofir Wolach, MD
Phone
+972-3-9378116
Email
ofirw@clalit.org.il
Facility Information:
Facility Name
Rambam Medical Center
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yishai Ofran, MD
Email
y_ofran@rambam.health.gov.il
Facility Name
Shaarei Tzedek Medical Center
City
Jerusalem
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacob Rowe, MD
Email
rowe@rambam.health.gov.il
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ofir Wolach, MD
Phone
+972-3-937-8116
Email
ofirw@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Miri Pinhasov, MA
Phone
+972-3-9378078
Email
miripi@clalit.org.il
Facility Name
Tel Aviv Medical Center
City
Tel Aviv
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yakir Moshe, MD PhD
Email
yakirm@tlvmc.gov.il

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
All data will be coded and uploaded to an electronic CRF (red-cap) to manage abnd analyze data

Learn more about this trial

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

We'll reach out to this number within 24 hrs